The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 17, 2018

Filed:

Mar. 14, 2014
Applicant:

The University of Chicago, Chicago, IL (US);

Inventors:

Yan Zheng, Chicago, IL (US);

Yuanyuan Zha, Chicago, IL (US);

Robbert M. Spaapen, Chicago, IL (US);

Thomas F. Gajewski, Chicago, IL (US);

Assignee:

The University of Chicago, Chicago, IL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); A61K 38/00 (2006.01); G01N 33/574 (2006.01); C12Q 1/68 (2018.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); C12N 15/113 (2010.01); G06F 19/00 (2018.01); G01N 33/569 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); C12N 15/113 (2013.01); C12N 15/1137 (2013.01); C12N 15/1138 (2013.01); G01N 33/56972 (2013.01); G01N 33/57484 (2013.01); G06F 19/3431 (2013.01); C12N 2310/14 (2013.01); C12N 2320/30 (2013.01); C12N 2320/31 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01);
Abstract

Embodiments concern methods and composition related to anergic T-cells in patients, such as cancer patients. T cell anergy is a hyporesponsive state induced by TCR engagement in the absence of costimulation (Schwartz, 2003). Anergy induction was initially observed in vitro using chemically-fixed antigen presenting cells (APCs). Subsequently, it was found that anergy could be induced by immobilized anti-CD3 mAb or calcium ionophores (such as ionomycin) in vitro, and by superantigen and soluble antigenic peptide in vivo. Indirect evidence has suggested that T cell dysfunction in the tumor microenvironment and establishment of transplant tolerance is partially due to T cell anergy (Gajewski et al., 2011).


Find Patent Forward Citations

Loading…